Xvivo Perfusion AB
STO:XVIVO

Watchlist Manager
Xvivo Perfusion AB Logo
Xvivo Perfusion AB
STO:XVIVO
Watchlist
Price: 282.4 SEK -5.87% Market Closed
Market Cap: kr8.9B

EV/EBIT

92.3
Current
66%
Cheaper
vs 3-y average of 271.4

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
92.3
=
Enterprise Value
kr7.8B
/
EBIT
kr94.4m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
92.3
=
Enterprise Value
kr7.8B
/
EBIT
kr94.4m

Valuation Scenarios

Xvivo Perfusion AB is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (271.4), the stock would be worth kr830.34 (194% upside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-83%
Maximum Upside
+194%
Average Upside
6%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 92.3 kr282.4
0%
3-Year Average 271.4 kr830.34
+194%
5-Year Average 86.6 kr264.9
-6%
Industry Average 15.5 kr47.3
-83%
Country Average 17.8 kr54.46
-81%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
kr7.8B
/
Jan 2026
kr94.4m
=
92.3
Current
kr7.8B
/
Dec 2026
kr145.2m
=
53.6
Forward
kr7.8B
/
Dec 2027
kr262.3m
=
29.7
Forward
kr7.8B
/
Dec 2028
kr401.9m
=
19.4
Forward
kr7.8B
/
Dec 2029
kr872.5m
=
8.9
Forward
kr7.8B
/
Dec 2030
kr1.3B
=
6
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
SE
Xvivo Perfusion AB
STO:XVIVO
8.9B SEK 92.3 353.5
US
Medline Inc
NASDAQ:MDLN
58.8B USD 0 0
JP
Hoya Corp
TSE:7741
9.7T JPY 33.6 38.6
CH
Alcon AG
SIX:ALC
29.2B CHF 28 37.3
DK
Coloplast A/S
CSE:COLO B
94.7B DKK 14.9 23.5
US
Align Technology Inc
NASDAQ:ALGN
13.5B USD 19.7 33
UK
ConvaTec Group PLC
LSE:CTEC
4.3B GBP 17.9 32.7
CA
Bausch + Lomb Corp
NYSE:BLCO
5.6B USD 54.5 -15.5
JP
Asahi Intecc Co Ltd
TSE:7747
890.2B JPY 32.4 50.3
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
37.3B CNY 20.3 22.6
KR
HLB Inc
KOSDAQ:028300
8T KRW -76.7 -36.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Xvivo Perfusion AB
STO:XVIVO
Average EV/EBIT: 34.8
92.3
62%
1.5
US
M
Medline Inc
NASDAQ:MDLN
Not Available
18%
N/A
JP
Hoya Corp
TSE:7741
33.6
N/A N/A
CH
Alcon AG
SIX:ALC
28
26%
1.1
DK
Coloplast A/S
CSE:COLO B
14.9
7%
2.1
US
Align Technology Inc
NASDAQ:ALGN
19.7
21%
0.9
UK
ConvaTec Group PLC
LSE:CTEC
17.9
21%
0.9
CA
Bausch + Lomb Corp
NYSE:BLCO
54.5
72%
0.8
JP
A
Asahi Intecc Co Ltd
TSE:7747
32.4
N/A N/A
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
20.3
10%
2
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -76.7 N/A N/A
P/E Multiple
Earnings Growth PEG
SE
Xvivo Perfusion AB
STO:XVIVO
Average P/E: 73.9
353.5
131%
2.7
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
JP
Hoya Corp
TSE:7741
38.6
15%
2.6
CH
Alcon AG
SIX:ALC
37.3
32%
1.2
DK
Coloplast A/S
CSE:COLO B
23.5
21%
1.1
US
Align Technology Inc
NASDAQ:ALGN
33
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
32.7
41%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -15.5 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
50.3
40%
1.3
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
22.6
9%
2.5
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -36.2 N/A N/A

Market Distribution

Higher than 96% of companies in Sweden
Percentile
96th
Based on 1 191 companies
96th percentile
92.3
Low
0.2 — 14
Typical Range
14 — 23.3
High
23.3 —
Distribution Statistics
Sweden
Min 0.2
30th Percentile 14
Median 17.8
70th Percentile 23.3
Max 4 325.3

Xvivo Perfusion AB
Glance View

Market Cap
8.9B SEK
Industry
Health Care

Nestled within the innovative landscape of Gothenburg, Sweden, Xvivo Perfusion AB stands at the forefront of transforming organ transplantation. Founded with the mission to tackle the chronic shortage of viable organs for transplant, Xvivo focuses primarily on improving the quality and availability of donor organs. At the heart of their operations is the development of advanced perfusion systems and solutions that enhance the viability of organs during transport and storage. By extending the window within which organs can remain functional outside the body, Xvivo's technology dramatically improves the chances of successful transplantation, while simultaneously expanding the pool of usable organs. Their product portfolio includes systems such as the XPS (Xvivo Perfusion System) and STEEN Solution™, specifically designed for lung and other visceral transplants to keep organs in optimal condition until the moment they are surgically implanted. Xvivo Perfusion monetizes its innovations through the sale of its proprietary equipment, perfusion liquids, and accompanying services to hospitals and transplant centers worldwide. The company strategically leverages its expertise in perfusion technology to not only enhance procedures but also cater to niche markets like ex vivo lung perfusion (EVLP), which provides additional preparation and evaluation of the organs before transplantation. Contracts, collaborative partnerships with research institutions, and long-term relationships nurtured within the medical community fuel Xvivo's growth trajectory. Additionally, their business model includes potential expansions into other areas of organ care and preservation, promising a future where transplant medicine continues to evolve, setting new standards and saving more lives. With sustained investments in research and a proactive approach to regulatory needs, Xvivo maintains its position as a crucial player within this life-saving industry, combining advanced science with compassionate healthcare solutions.

XVIVO Intrinsic Value
118.25 SEK
Overvaluation 58%
Intrinsic Value
Price kr282.4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett